AC
NTLA icon

Armistice Capital’s Intellia Therapeutics NTLA Stock Holding History

Armistice Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.4M Buy
1,500,000
+1,164,000
+346% +$16.3M 0.31% 51
2026
Q1 		$4.31M Sell
336,000
-820,000
-71% -$10.4M 0.08% 129
2025
Q4 		$10.4M Buy
1,156,000
+484,000
+72% +$6.66M 0.12% 100
2025
Q3 		$11.6M Buy
672,000
+22,000
+3% +$271K 0.17% 79
2025
Q2 		$6.1M Buy
650,000
+286,000
+79% +$2.35M 0.11% 90
2025
Q1 		$2.59M Buy
+364,000
New +$3.68M 0.04% 139

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Armistice Capital's NTLA Position: Q2 2026 in Review

Armistice Capital increased its Intellia Therapeutics (NTLA) stake by 346% in Q2 2026, buying an estimated $16.3M and bringing the position to 1,500,000 shares worth $25.4M. The position accounts for 0.31% of the portfolio, ranked #51.

Armistice Capital first reported a position in NTLA in Q1 2025 and has held it in 6 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Armistice Capital held 1,500,000 shares of Intellia Therapeutics worth $25.4M as of Q2 2026.
  • Armistice Capital bought 1,164,000 Intellia Therapeutics shares in Q2 2026, an estimated $16.3M.
  • Intellia Therapeutics made up 0.31% of Armistice Capital's portfolio in Q2 2026, its #51 holding.
  • Armistice Capital first reported a position in Intellia Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.